Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tetraphase Pharmaceu (TTPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,820
  • Shares Outstanding, K 53,626
  • Annual Sales, $ 9,670 K
  • Annual Income, $ -114,750 K
  • 36-Month Beta 2.89
  • Price/Sales 3.55
  • Price/Cash Flow N/A
  • Price/Book 0.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.36
  • Number of Estimates 5
  • High Estimate -0.19
  • Low Estimate -0.42
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +21.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.11 +5.41%
on 01/30/19
1.47 -20.41%
on 01/16/19
-0.25 (-17.61%)
since 01/15/19
3-Month
1.01 +15.84%
on 12/31/18
1.97 -40.61%
on 11/16/18
-0.78 (-40.00%)
since 11/15/18
52-Week
1.01 +15.84%
on 12/31/18
4.49 -73.94%
on 06/15/18
-1.03 (-46.82%)
since 02/15/18

Most Recent Stories

More News
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Tetraphase Pharmaceuticals, Inc. (TTPH) and Encourages TTPH Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH).

TTPH : 1.17 (-1.68%)
Robbins Arroyo LLP: Shareholders Allege That Tetraphase Pharmaceuticals, Inc. (TTPH) Misled Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Tetraphase Pharmaceuticals, Inc. (NasdaqGS: TTPH) filed a class action complaint against the...

TTPH : 1.17 (-1.68%)
New Research: Key Drivers of Growth for Tetraphase Pharmaceuticals, Olympic Steel, Belden, KAR Auction Services, BWX Technologies, and Sparton -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tetraphase Pharmaceuticals,...

ZEUS : 19.48 (-1.72%)
BDC : 56.64 (+1.25%)
SPA : 18.46 (+0.05%)
KAR : 54.51 (+0.61%)
BWXT : 51.45 (+2.72%)
TTPH : 1.17 (-1.68%)
Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 1.17 (-1.68%)
Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Resonant Inc. (NASDAQ:RESN),...

LIVN : 100.49 (+6.42%)
RESN : 3.30 (unch)
STZ : 174.91 (+0.55%)
PEN : 155.57 (+1.32%)
MASI : 129.62 (+0.63%)
TTPH : 1.17 (-1.68%)
Technological Advancements Show Growth in the Hospital Acquired Infection Control Market

According to data compiled by Mordor Intelligence, the Hospital Acquired Infection Control Market is expected to reach USD 33.78 Billion by 2021 and is growing at a CAGR of 8.3% during the forecasted....

AKAO : 0.92 (-35.35%)
SCYX : 1.38 (+0.73%)
RIGL : 2.40 (+5.73%)
PCTL : 0.1800 (-10.00%)
TTPH : 1.17 (-1.68%)
Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates

Tetraphase (TTPH) delivered earnings and revenue surprises of -5.71% and -44.93%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

TTPH : 1.17 (-1.68%)
Tetraphase: 3Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Tetraphase Pharmaceuticals Inc. (TTPH) on Thursday reported a loss of $19.6 million in its third quarter.

TTPH : 1.17 (-1.68%)
Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

XERAVA (eravacycline) Now Available to Hospitals in the United States

TTPH : 1.17 (-1.68%)
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today...

TTPH : 1.17 (-1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade TTPH with:

Business Summary

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug...

See More

Key Turning Points

2nd Resistance Point 1.24
1st Resistance Point 1.20
Last Price 1.17
1st Support Level 1.15
2nd Support Level 1.14

See More

52-Week High 4.49
Fibonacci 61.8% 3.16
Fibonacci 50% 2.75
Fibonacci 38.2% 2.34
Last Price 1.17
52-Week Low 1.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar